NAS
RLAY icon

Nykredit A/S’s Relay Therapeutics RLAY Stock Holding History

Nykredit A/S’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.6K Buy
+993
New +$14.4K ﹤0.01% 1752

Other funds holding RLAY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nykredit A/S's RLAY Position: Q2 2026 in Review

Nykredit A/S opened a new position in Relay Therapeutics (RLAY) in Q2 2026: 993 shares worth $18.6K. The stake represents ﹤0.01% of the portfolio and ranks #1752 among its holdings.

162 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Nykredit A/S held 993 shares of Relay Therapeutics worth $18.6K as of Q2 2026.
  • Relay Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Relay Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1752 holding.
  • 162 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.